Literature DB >> 10522505

IgE-mediated reactions and hyperreactivity in pregnancy rhinitis.

E Ellegård1, G Karlsson.   

Abstract

OBJECTIVES: To determine whether respiratory allergy or hyperreactive nasal mucosa is exceptionally common in women with pregnancy rhinitis, and to evaluate other possible risk factors such as clinical asthma or rhinitis, smoking, age, parity, and sex of the child. PATIENTS AND METHODS: From an antenatal questionnaire study, 165 women, 83 (50%) of whom had had pregnancy rhinitis, were examined 6 months after delivery, and multiple antigen simultaneous testing chemiluminescent assay (MAST CLA) (10 airborne allergens) was performed. After histamine provocations, rhinostereometry and acoustic rhinometry were performed in 25 of them. Serum levels of soluble intercellular adhesion molecule-1 were determined 4 times during and once after pregnancy in 5 women with pregnancy rhinitis and 17 without pregnancy rhinitis.
RESULTS: Thirty-nine women (24%) were sensitized to 1 or more allergen. The pregnancy rhinitis group showed significantly higher levels of IgE to house dust mites. There were also more smokers in the pregnancy rhinitis group. Clinical asthma or rhinitis, age, parity, and sex of the child did not differ significantly between the 2 groups. Mucosal swelling increased with rising concentrations of histamine, as measured with rhinostereometry, but there was no significant difference between the 2 groups in any of the variables. Serum soluble intercellular adhesion molecule-1 was not elevated in the pregnancy rhinitis group.
CONCLUSIONS: This study found no increased frequency of allergy in general in women who have had pregnancy rhinitis. However, IgE against house dust mite was more frequent in the pregnancy rhinitis group. Smoking seems to be a risk factor, but age, parity, sex of the child, and hyperreactive nasal mucosa do not. Soluble intercellular adhesion molecule-1 was not elevated during pregnancy rhinitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522505     DOI: 10.1001/archotol.125.10.1121

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

Review 1.  Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

Authors:  Rami Jean Salib; Peter Hugo Howarth
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Treating allergic rhinitis in pregnancy.

Authors:  Vincent Piette; Jean-Pierre Daures; Pascal Demoly
Journal:  Curr Allergy Asthma Rep       Date:  2006-05       Impact factor: 4.806

3.  Effect of Pregnancy on Vocal Cord Histology: An Animal Experiment.

Authors:  Serap Köybaşı Şanal; Yusuf Özgür Biçer; Aysel Kükner; Erkan Tezcan
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

Review 4.  Clinical and pathogenetic characteristics of pregnancy rhinitis.

Authors:  Eva K Ellegård
Journal:  Clin Rev Allergy Immunol       Date:  2004-06       Impact factor: 8.667

Review 5.  Treatment of allergic rhinitis during pregnancy.

Authors:  Pascal Demoly; Vincent Piette; Jean-Pierre Daures
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Role of VPAC1 and VPAC2 receptors in the etiology of pregnancy rhinitis: an experimental study in rats.

Authors:  Burak Ulkumen; Muhammet Burak Batir; Burcu Artunc Ulkumen; Halil Gursoy Pala; Seda Vatansever; Sirri Cam
Journal:  Braz J Otorhinolaryngol       Date:  2020-08-01

7.  Commentary on gender differences in prevalence, treatment, and quality of life of patients with chronic rhinosinusitis.

Authors:  Elisabeth H Ference; Bruce K Tan; Kathryn E Hulse; Rakesh K Chandra; Sean B Smith; Robert C Kern; David B Conley; Stephanie Shintani Smith
Journal:  Allergy Rhinol (Providence)       Date:  2015-01

Review 8.  Rhinitis and pregnancy: literature review.

Authors:  Fábio Azevedo Caparroz; Luciano Lobato Gregorio; Giuliano Bongiovanni; Suemy Cioffi Izu; Eduardo Macoto Kosugi
Journal:  Braz J Otorhinolaryngol       Date:  2015-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.